Prognostic significance of hMSH2, hMSH3, and hMSH6 expression in ameloblastoma

Autor(es):Mostrar menos -

do Amaral-Silva, Gleyson Kleber ; Sanchez-Romero, Celeste ; Wagner, Vivian Petersen ; Martins, Manoela Domingues ; Rebelo Pontes, Helder Antonio ; Fregnani, Eduardo Rodrigues ; Soares, Fernando Augusto ; de Almeida, Oslei Paes ; Rocha, Andre Caroli ; Santos-Silva, Alan Roger ; Fonseca, Felipe Paiva ; Vargas, Pablo Agustin

• Tipo de documento: Artigo Científico
• Fonte: ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY; v. 124, n. 3, p. 286-295, SEP 2017.
• Citações Web of Science: 0

Resumo

Objective. The aim of this study was to investigate hMutS proteins in developing human tooth, ameloblastomas, and ameloblastic carcinoma and to determine whether the expression of these proteins has any prognostic potential. Study Design. Ten cases of developing human tooth, 39 ameloblastomas, and 2 ameloblastic carcinomas were used to determine the distribution of the proteins during the process of carcinogenesis. Simultaneously, another sample of 73 ameloblastomas was arranged in tissue microarray, and their clinical, microscopic, and radiographic features; treatment outcome; presence of BRAF-V600E mutation; and follow-up data were assessed to determine the prognostic relevance of the expression of hMutS (hMSH2, hMSH3, hMSH6) and Ki-67. hMSH2 and hMSH6 were significantly downexpressed in ameloblastomas (P = .0059) compared with developing human tooth (P <.0001). Results. hMSH2, hMSH3 expression were significantly associated with BRAF-V600E mutation (P <.05). Simultaneous overexpression of hMutS was associated with recurrence (P =.035); however, these did not predict the disease-free survival of patients (P >.05). Conclusions. hMutS proteins are downregulated in ameloblastoma; moreover, simultaneous overexpression of these proteins in ameloblastoma was associated with recurrence but did not predict disease-free survival. (AU)

• Processo FAPESP: 15/21520-8 - Análise da expressão de proteínas relacionadas ao reparo do DNA, anti-apoptose e proliferação celular em ameloblastoma e carcinoma ameloblástico
• Beneficiário: Gleyson Kleber do Amaral Silva
• Modalidade de apoio: Bolsas no Brasil - Mestrado